secukinumab · Cosentyx
Monoclonal antibody
Also known as AIN457
Evidence outlook
Approved: Psoriasis, Psoriatic Arthritis, Hidradenitis Suppurativa
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (6)
- Ankylosing spondylitis and non-radiographic axial spondyloarthritis, adult and paediatric
- Active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older
- Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy (Novartis release dated 2019-04-02)
- Moderate to severe plaque psoriasis in adults (first indication); current label includes psoriatic arthritis, ankylosing spondylitis, nr-axSpA, HS, ERA/JPsA
- Psoriasis vulgaris and psoriatic arthritis in adults not adequately controlled by systemic therapies; first approval worldwide
- COSENTYX® (secukinumab injection/secukinumab for injection) is indicated for: Adult patients Plaque psoriasis COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Psoriatic arthritis COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. COSENTYX can be used alone or in combination with methotrexate (see 14.1.1 Psoriatic arthritis). Axial...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
FIXTURE NCT01358578 · Chronic Plaque Psoriasis This was a large, randomized, quadruple-blind trial with both placebo and active etanercept comparator groups, enrolling 1,306 participants. The clinical primary endpoints at week 12 were met in the favorable direction based on the reported counts: PASI 75 and IGA 0/1 responses were achieved by large majorities of secukinumab-treated participants compared with very few placebo-treated participants, although formal statistical analyses are not posted in the registry. Registry: NCT01358578 | 3 | Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks); Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator's Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12 (12 wks) 2013-07 | Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks): AIN457 150mg 219/327 (67.0%) | AIN457 300mg 249/323 (77.1%) vs Placebo 16/324 (4.9%) | Reliable signal | link ↗ |
View 7 more trials
ERASURE NCT01365455 · Moderate to Severe Plaque-type Psoriasis This is a randomized, quadruple-blind, placebo-controlled Phase 3 trial with 738 participants, which provides robust statistical power. The co-primary endpoints at Week 12 were PASI 75 response and IGA 0/1 response, both hard clinical/endoscopic outcome measures for psoriasis, and both were clearly met for each secukinumab dose versus placebo, with large absolute differences in response rates. Registry: NCT01365455 | 3 | Percentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks; Percentage of Participants Who Achieved (Investigator's Global Assessment) IGA Score of 0 or 1 (12 weeks) 2013-04 | Percentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks (12 weeks): AIN457 150 mg 71.6% | AIN457 300 mg 81.6% vs Placebo 4.5% | Reliable signal | link ↗ |
FEATURE NCT01555125 · Psoriasis The trial was randomized, double-blind, placebo-controlled, and included 177 participants, with clinical psoriasis endpoints that were statistically significant in favor of both secukinumab doses at week 12. The evidence is graded moderate because the record does not report a power or sample-size calculation, so adequate powering cannot be confirmed. Registry: NCT01555125 | 3 | Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis at Week 12 Measure: PASI 75 (Psoriasis Area and Severity Index) Response. (12 weeks); Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator's Global Assessment) With a 0 or 1 Response at Week 12 (12 weeks) 2016-10-24 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
JUNCTURE NCT01636687 · Psoriasis The induction phase was randomized, quadruple-blind, and placebo-controlled, with 182 participants (approximately 60 per group), and its clinical psoriasis endpoints were met: PASI 75 response was 71.7% with 150 mg and 86.7% with 300 mg versus 3.3% with placebo, while IGA 0/1 response was 53.3%, 73.3%, and 0%, respectively (all reported p<0.0001). A power calculation is not reported in the provided record, so the trial supports a moderate rather than strong evidence grade despite its otherwise rigorous design. Registry: NCT01636687 | 3 | Psoriasis Area and Severity Index (PASI) 75 Response and Investigators' Global Assessment (IGA) Mod 2011 0 or 1 Response (12 weeks) 2016-10-27 | Psoriasis Area and Severity Index (PASI) 75 Response and Investigators' Global Assessment (IGA) Mod 2011 0 or 1 Response (12 weeks): AIN457 150 mg — PASI 75: 71.7%; IGA 0/1: 53.3% | AIN457 300 mg — PASI 75: 86.7%; IGA 0/1: 73.3% vs Placebo — PASI 75: 3.3%; IGA 0/1: 0% | Partial signal | link ↗ |
SCALP NCT02267135 · Psoriasis The trial was randomized, quadruple-blind, and placebo-controlled, with 51 participants per group, and its clinical primary endpoint was statistically met. However, the supplied record does not report a power calculation, so the trial’s adequate powering cannot be confirmed; it therefore provides moderate rather than strong evidence. Registry: NCT02267135 | 3 | Psoriasis Scalp Severity Index 90 (PSSI 90) (12 weeks) 2015-12-07 | Psoriasis Scalp Severity Index 90 (PSSI 90) (12 weeks): Secukinumab 52.9% vs Placebo 2% | Partial signal | link ↗ |
ALLURE NCT02748863 · Psoriasis This was a randomized, quadruple-blind, placebo-controlled phase 3 trial in 214 patients, and both co-primary endpoints, PASI 75 and IGA 0/1 response at Week 12 for the 2 mL syringe versus placebo, were met (64 of 72 vs 1 of 71 and 55 of 72 vs 1 of 71; p<0.0001 for each). The protocol's sample-size calculation planned 70 patients per group, and each group enrolled at least 71. Registry: NCT02748863 | 3 | Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment; Participants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment 2017-08-08 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
MATURE NCT03589885 · Psoriasis Patients were randomly assigned to secukinumab or placebo, with patients, investigators and assessors all blinded. The protocol's power calculation called for 40 patients per group and each group enrolled at least 40; both secukinumab groups beat placebo on both primary skin-clearance measures at week 12 (p<0.0001). Registry: NCT03589885 | 3 | PASI 75 Response After 12 Weeks of Treatment; IGA Mod 2011 0 or 1 Response After 12 Weeks of Treatment 2019-11-19 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT02471144 NCT02471144 · Psoriasis This was a randomized, double-blind, placebo-controlled phase 3 trial in 162 children, and both co-primary endpoints, PASI 75 and IGA 0/1 response at Week 12, were met for both secukinumab doses versus placebo (p<0.0001 for each). The protocol's sample-size calculation planned 40 patients per group, and each group enrolled at least 40. Registry: NCT02471144 | 3 | Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12 (12 weeks); Number and Percentage of Participants Who Showed Investigator's Global Assessment (IGA) Mod 2011 Response of 0 or 1 at Week 12 (12 Weeks) 2018-12-13 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (89)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (41)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (37)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (15)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Appears in other studies (3)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 4 (2)
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other IL-17 drugs
ixekizumab, netakimab, vunakizumab. Compare all 4 IL-17 drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Hidradenitis Suppurativa: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Secukinumab (Cosentyx): this drug | Approved | Monoclonal antibody | IL-17 | Partial signal | NCT03713632: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): AIN457 Q2W 42.3 Percentage of Participants | AIN457 Q4W 46.1 Percentage of Participants | Placebo 31.2 Percentage of Participants NCT03713619: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): Secukinumab 1 - Q2W 45 Percentage of participants | Secukinumab 2 - Q4W 41.8 Percentage of participants | Placebo 33.7 Percentage of participants | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | Partial signal | NCT04242498: HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results). NCT04242446: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 (Week 16): Placebo 28.7 percentage of participants (95% CI 18.1 to 39.3) | BKZ Dosing Regimen 1 45.3 percentage of participants (95% CI 36.8 to 53.8) | BKZ Dosing Regimen 2 47.8 percentage of participants (95% CI 41.8 to 53.7) | |
| Lutikizumab | Phase 3 | Multispecific antibody | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Remibrutinib | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded | No reviewed efficacy summary in this indication | |
| Ruxolitinib (Opzelura) | Phase 3 | Small molecule | JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sonelokimab | Phase 3 | Antibody-derived scaffold | IL-17A/F | not yet graded | No reviewed efficacy summary in this indication | |
| Upadacitinib (Rinvoq) | Phase 3 | Small molecule | JAK, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| BFB759 | Phase 2/3 | Monoclonal antibody | IL-1RAP | not yet graded | No reviewed efficacy summary in this indication | |
| Spesolimab (Spevigo) | Phase 2/3 | Monoclonal antibody | IL-36 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Abdakibart | Phase 2 | Monoclonal antibody | IL-1 beta | not yet graded | No reviewed efficacy summary in this indication | |
| Duvakitug | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Eltrekibart | Phase 2 | Monoclonal antibody | CXCR1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Olatorepatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| ORKA-002 | Phase 2 | Monoclonal antibody | IL-17A/F | not yet graded | No reviewed efficacy summary in this indication | |
| SAR442970 | Phase 2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| SAR445399 | Phase 2 | Monoclonal antibody | IL-1R3 (IL1RAP) | not yet graded | No reviewed efficacy summary in this indication | |
| SPY072 | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Tulisokibart | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Zasocitinib | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-1451 | Phase 1(overall) | Undisclosed | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| SAR447971 | Phase 1(overall) | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Tipasertideg | Discontinued | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(15 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Cosentyx (secukinumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
June 2027 (1)
What to watch
August 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (7)
January 2028 (1)
What to watch
February 2028 (1)
What to watch
March 2028 (1)
May 2028 (2)
September 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (3)
September 2029 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent